News
InVitria and Cellevate Partner on Vaccine Manufacturing
Article · Published 2026-03-12 · 1 min read
Partnership explores upstream bioprocessing approaches for scalable viral vaccine production
InVitria has entered a strategic collaboration with Cellevate AB to explore improved upstream solutions for viral vaccine production.

The collaboration brings together Cellevate’s Cellevat3d® nanofiber microcarrier platform with InVitria’s chemically defined recombinant proteins to support scalable, animal-origin-free vaccine manufacturing workflows.
Cellevat3d enables high-density adherent cell culture, while InVitria’s recombinant media components help provide consistent and defined culture conditions for biomanufacturing.
Together, these technologies aim to support developers of viral vaccines and viral vector-based therapeutics.
Read the full announcement from Cellevate:
Cellevate AB and InVitria Inc. enter strategic collaboration to advance upstream bioprocessing solutions for viral vaccine production
More resources
Keep reading.
Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing
InVitria Joins NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)
Talk to a Scientist
See how rHSA performs in your media.
Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.